Issue 6, 2024

Pt(iv) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

Abstract

Cancer remains a significant global health challenge, necessitating continuous advancements in therapeutic strategies. Chemotherapeutic agents have long been pivotal in cancer treatment, with platinum(Pt)-based drugs holding a prominent place. Oxaliplatin, a third-generation Pt(II) compound, has gathered attention for its efficacy towards several cisplatin-resistant cancer cells and has become the front-line therapy for metastatic colorectal cancer. However, inherent limitations such as resistance development and dose-dependent side effects like oxaliplatin-induced peripheral neuropathy (OIPN) prompt the exploration of novel derivatives. Pt(IV) prodrugs have emerged as a promising avenue in cancer therapy, exploiting the intrinsic cytotoxicity of platinum while offering enhanced stability and tunable pharmacokinetics. However, the majority of Pt(IV) prodrugs reported in the literature, for their in vitro or in vivo anticancer properties, are cisplatin-based. This comprehensive review gathers, to our knowledge, the recent advances on oxaliplatin-based Pt(IV) derivatives and how they can strategically address the aforementioned challenges.

Graphical abstract: Pt(iv) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

Article information

Article type
Review Article
Submitted
17 Des 2023
Accepted
20 Jan 2024
First published
24 Jan 2024

Inorg. Chem. Front., 2024,11, 1639-1667

Pt(IV) anticancer prodrugs bearing an oxaliplatin scaffold: what do we know about their bioactivity?

A. Lopez-Sanchez and H. C. Bertrand, Inorg. Chem. Front., 2024, 11, 1639 DOI: 10.1039/D3QI02602G

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements